Tenofovir Alafenamide Fumarate (TAF) effect on residual intrathecal immune activation
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 02 Jan 2018 Planned End Date changed from 1 Oct 2017 to 31 Mar 2018.
- 02 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 31 Mar 2018.
- 02 Jan 2018 Status changed from recruiting to active, no longer recruiting.